Cluster 0: lifestyle abstinence usual contraception acceptable preferred symptothermal ovulation methods method
Cluster 1: transplantation autologous cell allogeneic stem hematopoietic prior organ patients history
Cluster 2: investigational participation clinical drug trial study agent days involving participated
Cluster 3: surgery breast mastectomy undergo radiation erythema patients lumpectomy definitive planned
Cluster 4: safety medical unstable condition jeopardize compliance generally judgment provision reasonable
Cluster 5: understand informed consent sign willing form written power able benefits
Cluster 6: seronegative donor antibody human hiv immunodeficiency virus intact lymphotropic seropositive
Cluster 7: viral hepatitis infection positive active known chronic hiv cmv history
Cluster 8: red packed blood cell transfusions transfusion hemoglobin days dl rbc
Cluster 9: lipase pancreatitis radiologic uln clinical evidence institutions definitive residual suggestive
Cluster 10: containing regimen refractory treatment therapy prior irinotecan received chemotherapy star
Cluster 11: clearance creatinine min measured ml serum calculated renal uln estimated
Cluster 12: sexually contraception childbearing women accepted use medically males effective able
Cluster 13: previous received chemotherapy prior treatment weeks therapy dose cytotoxic cancer
Cluster 14: bilirubin upper total uln limit normal level institutional registration days
Cluster 15: association york heart new myocardial infarction class angina unstable failure
Cluster 16: significant cardiac history heart ecg hypertension qt restrictive causes embolism
Cluster 17: mm count neutrophil absolute anc bil cu days cells registration
Cluster 18: randomized hours ii urine phase negative test pregnancy serum existing
Cluster 19: symptomatic brain metastases require symptoms steroids control requiring treated uncontrolled
Cluster 20: gog performance status oncology group protocol patients appendix better good
Cluster 21: presence confirmed metastatic systemic patient known disease therapy prior patients
Cluster 22: renal hematologic hepatic defined adequate function coagulation inadequate cardiac liver
Cluster 23: nervous central cns metastases brain treated stable metastasis active neurologically
Cluster 24: recist presence measurable radiographically extranodal based determined disease site evaluable
Cluster 25: judged willingness provide written investigator informed consent voluntarily disability medically
Cluster 26: aminotransferase alanine alt ast aspartate uln liver metastases times hepatic
Cluster 27: radiotherapy radiation weeks palliative treatment start therapy prior study received
Cluster 28: older males lactating available females breastfeeding age pregnant non years
Cluster 29: test pregnancy negative female potential serum urine childbearing feeding days
Cluster 30: scan imaging bone lesions metastasis ct disease metastatic metastases cross
Cluster 31: progressing additional requires exceptions required past potentially curative basal malignancy
Cluster 32: months time days patients weeks study prior treatment enrollment therapy
Cluster 33: inducers moderate strong cypa inhibitors dose use days study prior
Cluster 34: carcinoma basal situ malignancy cell low curative resection squamous skin
Cluster 35: histologically cytologically confirmed unresectable metastatic diagnosis adenocarcinoma cancer patients pathologically
Cluster 36: cycle anti weeks day investigational prior therapy days treatment chemotherapy
Cluster 37: events adverse biologic hazardous xrt days agent underlying make infusion
Cluster 38: anticancer alopecia grade ctcae unresolved recovered toxicities toxicity previous aes
Cluster 39: solid advanced standard tumors metastatic histologically available therapy tumor benefit
Cluster 40: illness psychiatric medical informed abnormality consent prevent laboratory significant condition
Cluster 41: comply able procedures willing follow protocol subject prospective aspects examinations
Cluster 42: diabetes hbac glucose mellitus poorly fasting controlled glycated glycosylated ac
Cluster 43: products hypersensitivity known allergy ingredients intolerance reactions reaction history suspected
Cluster 44: total dl bilirubin mg direct ml serum days equal umol
Cluster 45: pressure hypertension systolic blood diastolic mmhg uncontrolled bp controlled despite
Cluster 46: systemic modifying treatment autoimmune required past active immunosuppressive disease years
Cluster 47: antibiotics infection parenteral requiring active systemic infections acute prophylaxis anti
Cluster 48: matched donor unrelated hla related allele drb sibling haploidentical donors
Cluster 49: ecog status scale performance acceptable subject patients ipss symptom mf
Cluster 50: therapy treatment study radiation weeks prior received dose chemotherapy eligible
Cluster 51: severe chronic liver evidence history infections hepatic clinically disease acute
Cluster 52: congestive myocardial arrhythmia heart infarction failure symptomatic cardiac significant disease
Cluster 53: glutamic oxaloacetic sgot transaminase aminotransferase sgpt serum pyruvate glutamate upper
Cluster 54: cervical situ skin carcinoma melanoma malignancy non years cancer melanomatous
Cluster 55: expiratory fev forced predicted volume dlco capacity second carbon monoxide
Cluster 56: normalized international inr ratio thromboplastin prothrombin time pt aptt activated
Cluster 57: vomiting nausea bowel resection refractory absorption significant preclude diseases malabsorption
Cluster 58: old years age male greater time aged adult donor patients
Cluster 59: affecting gastrointestinal malabsorption significantly oral unable disease syndrome integrity requirement
Cluster 60: tolerate oral swallow ability patients receive inability unable medications able
Cluster 61: heparin low molecular warfarin anticoagulation weight therapeutic dose aspirin lmwh
Cluster 62: resection surgical tumor radiation hematuria residual hemoptysis therapy intent disease
Cluster 63: attack transient ischemic tia months history cva consciousness unexplained loss
Cluster 64: ventricular tachycardia fibrillation degree atrial block arrhythmias lvef old arrhythmia
Cluster 65: birth control method agree childbearing potential use effective study women
Cluster 66: english read spanish able speak understand unable ability caregiver inability
Cluster 67: compromise opinion investigator condition medical safety ability illness study patient
Cluster 68: placement minor access major surgery excluding device vascular surgical procedures
Cluster 69: breast cancer received metastatic chemotherapy prior disease neoadjuvant therapy docetaxel
Cluster 70: hour ratio protein urine creatinine urinalysis proteinuria mg cabozantinib gram
Cluster 71: nsclc small stage lung confirmed non cell cancer cytologically carcinoma
Cluster 72: equivalent prednisone mg dose corticosteroid doses corticosteroids day chronic systemic
Cluster 73: inclusion exclusion criteria apply additional infection procurement expectancy regarding pembrolizumab
Cluster 74: lower magnesium lln potassium calcium phosphorus serum limit supplementation normal
Cluster 75: recent ongoing including illness evidence grade infection uncontrolled active patients
Cluster 76: invasive dcis ductal cancer situ breast carcinoma diagnosis history treated
Cluster 77: fap fanca fanconi fancd farber fancc zydelig fascia interested enrolment
Cluster 78: mature spermicide naturally consecutive bearing child effective potential women months
Cluster 79: nursing pregnant women following participate breastfeed included planning woman step
Cluster 80: ethics committee board independent review approved irb representative legal nature
Cluster 81: physician treating expectancy determined life greater months opinion investigator assessed
Cluster 82: dependence year alcohol abuse past current drug active event cerebrovascular
Cluster 83: tissue archived biopsy fresh tumor sample archival available provide excisional
Cluster 84: dimension cm tumors lesion greater tumor disease patients expansion expectancy
Cluster 85: surgery major weeks prior days study procedure day treatment patients
Cluster 86: mutations mutation testing clia raf braf breast melanoma cancer known
Cluster 87: procedures written specific informed consent signed study obtained prior related
Cluster 88: investigational weeks administration treatment prior therapy dose study initiation days
Cluster 89: directly cooperative eastern oncology group ecog performance status patients exists
Cluster 90: scan ct computed tomography mri imaging measurable emission positron disease
Cluster 91: seropositive human hiv immunodeficiency virus infection lymphotropic htlv eligible leukemia
Cluster 92: ejection fraction left ventricular cardiac shortening rest lvef greater function
Cluster 93: agree contraception use effective male method potential female study childbearing
Cluster 94: secretory macroglobulinemia lymphocytic lymphoma criteria expression exposure expiratory experimental experienced
Cluster 95: hbv hcv hepatitis infection hiv virus known immunodeficiency chronic active
Cluster 96: interfere opinion medical illness psychiatric investigators potentially completion protocol adherence
Cluster 97: receptor ihc estrogen negative breast progesterone er pr positive hybridization
Cluster 98: mcl hydroxyurea white mm blood count cells ul wbc days
Cluster 99: corticosteroids receiving systemic replacement treatment ongoing immunosuppressive patients agents chronic
Cluster 100: recovered surgery starting major effects weeks prior study therapy injury
Cluster 101: lung interstitial history pneumonitis disease active requiring evidence induced ongoing
Cluster 102: factor support growth neutrophil absolute count anc mcl days factors
Cluster 103: nature aware indicating anderson md investigational center risks informed consent
Cluster 104: score performance karnofsky status scale kps lansky ps greater pediatric
Cluster 105: interval prolongation qtc baseline qt males msec ecg corrected screening
Cluster 106: leukemias secretory burkitt accelerated leukemia chronic fatty inherited myelogenous alcoholic
Cluster 107: terminology common events adverse ctcae criteria grade neuropathy event existing
Cluster 108: platelet untransfused count randomization cells mm obtained days prior thrombocytopenia
Cluster 109: neutrophil count absolute anc ul days cells registration prior mcl
Cluster 110: indication exercise pulse oximetry air dyspnea rest room intolerance evidence
Cluster 111: gault cockcroft clearance ml min creatinine formula calculated using estimated
Cluster 112: information authorization protected health release purpose risks signed personal regulations
Cluster 113: grade alopecia toxicity related therapy prior previous resolved treatment toxicities
Cluster 114: cr leukemia remission relapse complete risk disease favorable isolated solitary
Cluster 115: allowed chemotherapy therapy treatment radiation patients systemic prior received disease
Cluster 116: stage cancer iii diagnosed breast diagnosis metastatic iv ii patients
Cluster 117: hypersensitivity allergy components known reaction history nivolumab drug identified formulation
Cluster 118: gilbert syndrome bilirubin total uln disease unless mg dl normal
Cluster 119: function defined marrow bone adequate organ tests demonstrated evidenced laboratory
Cluster 120: cream spermicidal cap vaginal double diaphragm methods contraceptive contraception study
Cluster 121: pugh class hepatic child liver score cirrhosis classification impairment severe
Cluster 122: expression cd cells immunohistochemistry peripheral marrow blood bone positive tumor
Cluster 123: filtration glomerular rate gfr min ml creatinine renal estimated serum
Cluster 124: significant pulmonary clinically uncontrolled disease cardiovascular diseases active history metabolic
Cluster 125: cycle randomization day infections prior hemoglobin obtained severe dl enrollment
Cluster 126: program registered mandatory rems revlimid requirements comply willing able adhere
Cluster 127: imaging resonance mri magnetic brain contrast mr undergo ct metastases
Cluster 128: influenza live bcg attenuated vaccines cis induction approximately doses vaccination
Cluster 129: half lives whichever investigational drug shorter days longer dose agents
Cluster 130: bleeding disorder coagulopathy history known disorders psychiatric major significant bipolar
Cluster 131: parp inhibitor polymerase treatment olaparib prior inhibitors including previous received
Cluster 132: basal situ carcinoma skin squamous cell cervix treated malignancy years
Cluster 133: infectious pneumonitis non required steroids known evidence history current active
Cluster 134: anticoagulant range normalized inr intended pt ptt anticoagulants prothrombin time
Cluster 135: myelodysplastic myeloproliferative leukemia mds diagnosis cmml neoplasm excess blasts anemia
Cluster 136: organ solid transplant bone allogeneic stem marrow cell history prior
Cluster 137: events embolic attacks arterial venous transient cerebrovascular past months thromboembolic
Cluster 138: bacterial fungal antibiotics infection episode excluding intravenous infections acute time
Cluster 139: mother breastfeeding excluded pregnant women discontinued treated study nursing studied
Cluster 140: gilberts syndrome unless bilirubin total uln hyperbilirubinemia patients mg dl
Cluster 141: enrollment days drug study received use dose treatment investigational prior
Cluster 142: provide able informed consent written willing patient study trial patients
Cluster 143: earlier administered events adverse recovered weeks entering monoclonal antibody agents
Cluster 144: institute national nci common ctcae terminology grade adverse version cancer
Cluster 145: antiretroviral combination hiv immunodeficiency virus human positive therapy ineligible positivity
Cluster 146: ast limit upper normal aminotransferase alt aspartate uln alanine times
Cluster 147: targeting ctla pd checkpoint antibody anti pathway pdl targeted therapies
Cluster 148: host versus graft gvhd disease active stem allogeneic transplant chronic
Cluster 149: absorption metabolism gastrointestinal interfere significantly condition drug extensive disease rapamycin
Cluster 150: aml promyelocytic classification acute leukemia organization world diagnosis health favorable
Cluster 151: erythematosus lupus systemic autoimmune vasculitis sclerosis disease rheumatoid arthritis inflammatory
Cluster 152: psa ng prostate value ml rising serum vitamin prostatectomy initial
Cluster 153: years age men older male adult female time aged subjects
Cluster 154: steroid immunosuppressive form systemic therapy receiving immunodeficiency physiologic diagnosis intolerance
Cluster 155: investigational entry cancer currently patients receiving agents anti eligible study
Cluster 156: spinal compression cord brain metastases leptomeningeal carcinomatous meningitis stable ck
Cluster 157: pectoris arrhythmia angina unstable uncontrolled medication congestive failure illness symptomatic
Cluster 158: based regimen platinum chemotherapy received therapy anthracycline prior progression disease
Cluster 159: head neck cancer primary region edema dissection iii recurrent group
Cluster 160: occlusion retinal vein rvo csr history current superior portal invasion
Cluster 161: response measurable evaluation criteria recist tumors solid disease evaluable defined
Cluster 162: nervous cns central leukemia lymphoma active primary known patients leptomeningeal
Cluster 163: meningitis brain metastases trial enlarging neurologic carcinomatous returned evidence confound
Cluster 164: york association new nyha heart failure congestive class iii iv
Cluster 165: dl albumin days mg obtained registration hemoglobin prior treatment serum
Cluster 166: naturally consecutive hysterectomy postmenopausal undergone months mature menses preceding sexually
Cluster 167: peptic ulcer gastritis bleeding active uncontrolled spontaneous diathesis disease diatheses
Cluster 168: transfusions platelet days factors growth count erythropoietin help measured treatment
Cluster 169: attack transient ischemic angina myocardial infarction thromboembolic stroke arterial accident
Cluster 170: recist lesion measurable according defined disease presence site non criteria
Cluster 171: articular injections eye airways drops sprays applications rash topical inhaled
Cluster 172: mtor rapamycin inhibitor mammalian target inhibitors treatment prior pik pathway
Cluster 173: center pathology kettering mskcc sloan memorial diagnosis confirmed report slides
Cluster 174: local informed assent consent guidelines according written good international authorized
Cluster 175: body weight lbs experienced kg loss program significantly past donor
Cluster 176: contraception potential use agree childbearing men study effective adequate women
Cluster 177: polyneuropathy organomegaly changes endocrinopathy poems monoclonal protein skin gammopathy plasma
Cluster 178: muga fraction ejection echocardiogram acquisition echo gated left scan ventricular
Cluster 179: acquired testing human hiv immunodeficiency syndrome virus positive known aids
Cluster 180: second malignancy concurrent primary requiring active years treatment patients skin
Cluster 181: pump proton antacids antagonists use taken daily receptor enzymes uses
Cluster 182: ulcerative colitis bowel inflammatory crohns gastrointestinal crohn disease documented active
Cluster 183: wocbp method plus avoid contraception pregnancy use instructions entire duration
Cluster 184: metallic implants devices mri metal pacemakers contraindications claustrophobia implanted defibrillator
Cluster 185: paraffin tissue embedded formalin availability slides ffpe fixed archival tumor
Cluster 186: preparative receives elapsed toxicities recovered grade allow therapies palliation vitiligo
Cluster 187: iud established intrauterine device placement hormone contraceptive methods use releasing
Cluster 188: epithelial ovarian histologic primary endometrioid fallopian serous peritoneal mixed tube
Cluster 189: alkaline phosphatase liver uln limit bone alk upper normal present
Cluster 190: lymphoma transformed indolent dlbcl fl transformation follicular cell diffuse nhl
Cluster 191: surface virus hepatitis positive antigen hbv antibody negative rna ribonucleic
Cluster 192: macroglobulinemia myeloma waldenstrom amyloidosis gammopathy multiple workshop igm immunoglobulin failed
Cluster 193: conditions medical affect uncontrolled interfere psychiatric participation severe adherence sepsis
Cluster 194: accurately dimension longest mm recorded calipers axis measured diameter lesion
Cluster 195: upper normal limit gilberts bilirubin institutional times serum uln total
Cluster 196: calcium limits corrected normal lln magnesium albumin potassium range serum
Cluster 197: compliance safety compromise disorder psychiatric interfere allow does cause obtaining
Cluster 198: medical condition investigator interfere likely participation opinion study psychiatric compliance
Cluster 199: polysorbate reactions hypersensitivity docetaxel excipients allergic history growth containing reaction
Cluster 200: approved irb board review signed document institutional informed consent understand
Cluster 201: bacterial fungal viral infection uncontrolled active systemic infections unresponsive improvement
Cluster 202: cypa ritonavir inhibitors clarithromycin grapefruit itraconazole ketoconazole olaparib star narrow
Cluster 203: portion phase trial ib randomized expansion eligibility ii prior ecog
Cluster 204: intercurrent situations social arrhythmia compliance illness pectoris congenital ongoing unstable
Cluster 205: morbid inappropriate make judgment obtaining prescribed illnesses regimens significantly safety
Cluster 206: relapsed refractory multiple myeloma diagnosis therapy aml according prior patients
Cluster 207: mental altered prohibit dementia understanding informed consent psychiatric status cognitive
Cluster 208: currently pregnant feeding participant participants donor breast subjects women study
Cluster 209: rna hcv hepatitis ribonucleic acid antigen antibody virus positive pcr
Cluster 210: bearing child negative pregnancy potential urine test serum dosing measures
Cluster 211: pleural ascites paracentesis effusions effusion causes dyspnea respiratory randomization version
Cluster 212: light chain free protein mg serum ratio immunoglobulin abnormal involved
Cluster 213: year postmenopausal estradiol menopausal defined female months screening visit spontaneous
Cluster 214: arrhythmias arrhythmic cardiac requiring atrial fibrillation anti beta flutter therapy
Cluster 215: hemolytic purpura anemia thrombotic syndromes idiopathic fanconi thrombocytopenia syndrome failure
Cluster 216: procedure surgical traumatic injury major need anticipation open course significant
Cluster 217: diabetes insulin mellitus hypothyroidism uncontrolled type controlled hazardous patients diabetic
Cluster 218: excipients hypersensitivity known intolerance allergy drugs allergies classes formulations ribociclib
Cluster 219: follow visits able comply willing study visit schedule availability examinations
Cluster 220: illnesses disorders infections coagulation active major requiring infective falls restrictive
Cluster 221: electrocardiographic conduction ischemia heart uncontrolled abnormalities angina pacemaker relevant abnormality
Cluster 222: neuropathy grade peripheral ctcae pain enrollment initiation significant patient applicable
Cluster 223: expansion specific cohort phase criteria dose inclusion treatment participants escalation
Cluster 224: abscess abdominal fistula perforation gastrointestinal intra diverticulitis gi carcinomatosis obstruction
Cluster 225: compounds composition attributed chemical similar allergic reactions hypersensitivity biologic cabazitaxel
Cluster 226: correlative tissue provide blood specimens mandatory samples future studies research
Cluster 227: ginseng kava yohimbe ephedra ma herbal bisphosphonates prohibited medications concurrent
Cluster 228: rifampin st wort johns phenytoin carbamazepine inducers cypa herbal phenobarbital
Cluster 229: achieve intervention note hgb acceptable transfusion hemoglobin dl registration use
Cluster 230: live vaccine received days planned medication start treatment virus dose
Cluster 231: idiopathic pneumonia fibrosis pneumonitis organizing induced chest pulmonary extensive history
Cluster 232: hypokalemia lower mmol supplementation torsade corrected pointes additional long factors
Cluster 233: pd ctla anti immune inhibitor checkpoint treatment prior received pdl
Cluster 234: compliance regimens non medical survival unreliable expected regimen history staff
Cluster 235: clearance min creatinine ml levels serum limit upper institutional normal
Cluster 236: criteria inclusion treatment patients prior therapy study following exclusion eligible
Cluster 237: prostatectomy prostate cryosurgery cryotherapy beam external brachytherapy radiation radical therapy
Cluster 238: metastases brain symptomatic untreated excluded cns known clinical corticosteroids participants
Cluster 239: pack cigarettes smoking current cessation smoked tobacco self daily year
Cluster 240: specified protocol adhere visit schedule requirements willing able restrictions meet
Cluster 241: gender maximum age creatinine years male serum female mg dl
Cluster 242: mmol cholesterol fasting triglycerides levels serum mg dl case hypertriglyceridemia
Cluster 243: tki egfr tyrosine tm kinase bcr ph abl erlotinib generation
Cluster 244: swallow oral able unable medication tablet administration ability requirements comply
Cluster 245: donor member matched hla antigen family related leukocyte identical falls
Cluster 246: period lactating test screening female pregnancy positive serum breastfeeding urine
Cluster 247: effects recovered fully alopecia reversible grade chemotherapy toxic acute prior
Cluster 248: vulnerable incarcerated person prisoners individuals mentally impending persons involuntarily children
Cluster 249: level hemoglobin dl transfused hgb gram liter criterion albumin value
Cluster 250: hematopoietic transplant allogeneic stem cell hct months ci having sct
Cluster 251: medical disorder impair uncontrolled infection receive ability protocol superior poor
Cluster 252: willingness ability informed consent understand sign written form subjects document
Cluster 253: years melanoma cancers skin invasive cancer malignancy non malignancies situ
Cluster 254: bradycardia beats minute resting hr pacemaker medically rate ecg baseline
Cluster 255: return enrolling institution follow willing willingness clinic observation monitoring site
Cluster 256: karnofsky performance ecog status lansky greater years score patients equal
Cluster 257: discontinued weeks biologic registration radiation prior therapy days study directed
Cluster 258: inform immediately woman suspect pregnant participating physician study bearing treating
Cluster 259: glutamate pyruvate sgpt transaminase alanine alt aminotransferase uln serum upper
Cluster 260: dialysis failure renal requiring peritoneal hemodialysis contrast hematological requirement replacement
Cluster 261: places unacceptable participate data abnormalities condition reason undue interpretation artery
Cluster 262: neuropathy sensory peripheral grade preexisting existing pre baseline ctcae greater
Cluster 263: infection hepatitis evidence active uncontrolled systemic patients grade known pericardial
Cluster 264: exertion power lungs extensive dyspnea rest involvement lung evidence exist
Cluster 265: expectancy life weeks year predicted years greater subjects patient patients
Cluster 266: cll lymphoma richter transformation lymphocytic leukemia workshop hodgkin fl large
Cluster 267: interval corrected qt fridericia correction qtcf formula qtc msec ecg
Cluster 268: times institutional serum uln normal limits creatinine upper institution days
Cluster 269: bsa area body surface dose enrolled level patients time enrollment
Cluster 270: topical inhaled steroids immunosuppressive doses systemic corticosteroids replacement steroid chronic
Cluster 271: pregnancy breastfeeding women test positive lactating urine pregnant planning study
Cluster 272: hypertensive mmhg hypertension controlled inadequately crisis encephalopathy history pressure medications
Cluster 273: idiosyncrasy chemically delayed immediate reaction drugs related hypersensitivity known estrogen
Cluster 274: intact capsules swallow inability tablets unwilling unable able patients absorb
Cluster 275: lenalidomide bortezomib immunomodulatory refractory prior carfilzomib lines pomalidomide therapy applicable
Cluster 276: antibiotics iv oral requiring systemic infection suppressive active weeks intravenous
Cluster 277: guardian parent legal informed consent patient written providing signed copy
Cluster 278: assignment previous exposure treatment pomalidomide dexamethasone enrolment therapy combination study
Cluster 279: strong cytochrome cypa inhibitors inducers medications cypc use subfamily concomitant
Cluster 280: tuberculosis known history primary previous immunodeficiency subject active secondary eligibility
Cluster 281: deep thrombosis venous pulmonary embolism vein dvt months history arterial
Cluster 282: lymphocyte cytotoxic programmed death ligand ctla pd anti cell agonist
Cluster 283: adequate function defined following follows organ protocol days evidenced hematologic
Cluster 284: immune autoimmune disease history recur auto suppression suppressive inactive deficiency
Cluster 285: pelvis outside cavity portion abdominal radiotherapy radiation abdomen prior remains
Cluster 286: withdrawn prejudice voluntary future understanding care procedure medical consent given
Cluster 287: ado emtansine trastuzumab lapatinib dm setting therapy regimen prior chemotherapy
Cluster 288: abstinent remain agreement contraceptive sperm intercourse measures period rate year
Cluster 289: revascularization mi coronary ischemic symptoms events including cardiac history familial
Cluster 290: reactions allergic severe anaphylactic humanized antibodies reaction monoclonal anaphylaxis hypersensitivity
Cluster 291: assessment mmol initiation transfusion hemoglobin dl dependency erythropoietin days performed
Cluster 292: hypercalcemia levels calcium albumin corrected serum adjusted phosphate mmol institutional
Cluster 293: lymph regional nodes dissection node cm biopsy axillary lumpectomy disease
Cluster 294: setting adjuvant neoadjuvant lines metastatic chemotherapy therapy received prior line
Cluster 295: neuroendocrine small prostate carcinoma features cell tumors finding pancreatic poorly
Cluster 296: repair vascular peripheral aortic significant aneurysm arterial high clinically collagen
Cluster 297: lesions measurable target irradiated disease radiation cm recist lesion bone
Cluster 298: squamous carcinoma histologically cell adenocarcinoma confirmed oropharynx neck cancer gastric
Cluster 299: glioblastoma anaplastic glioma iii diagnosis grade experimental expression exposure expiratory
Cluster 300: adequate liver renal function hematological marrow bone hepatic laboratory metabolic
Cluster 301: pulse oximetry air room saturation oxygen pulmonary rest baseline ambulatory
Cluster 302: inability comply outlined protocol unwillingness required procedures study regulations federal
Cluster 303: stroke hemorrhage accident cerebral months cerebrovascular history enrollment intracranial hemorrhagic
Cluster 304: diathesis bleeding evidence coagulopathy anticoagulation significant correctable known inherited history
Cluster 305: block right anterior branch bundle conduction degree av resting abnormalities
Cluster 306: intermediate high risk prognostic scoring international neuroblastoma myelofibrosis mf revised
Cluster 307: sexually birth control men effective concluded practicing regarding condom partner
Cluster 308: vessels abutting vessel pulmonary major subject endobronchial radiographic invading increase
Cluster 309: nursing lactating female state intend hcg laboratory participants pregnancy eligible
Cluster 310: erythema thalidomide rash similar taking drugs extensive expression exposure expiratory
Cluster 311: healing wound fracture ulcer major surgery non injuries recovery trauma
Cluster 312: free years unless exception malignancies subject disease history considered outcome
Cluster 313: ajcc joint stage staging edition th committee american cancer iv
Cluster 314: leukemia blasts lymphoblastic acute relapsed myeloid remission aml marrow lymphoma
Cluster 315: stent intestinal biliary obstruction partial signs symptoms bowel evidence history
Cluster 316: seizure controlled disorder uncontrolled neurologic patients anticonvulsants epilepsy febrile antiepileptic
Cluster 317: thrombolytic anticoagulants therapeutic current use parenteral recent warfarin requires inr
Cluster 318: sociological familial psychological geographical follow compliance schedule potentially hampering protocol
Cluster 319: accordance federal guidelines written institutional nature informed consent investigational given
Cluster 320: concurrent investigational agents therapy treatment radiation chemotherapy use biological permitted
Cluster 321: fertile contraceptive men practice unwilling methods techniques exists documentation period
Cluster 322: stereotactic radiosurgery wbrt brain metastases radiation diameter asymptomatic lesions month
Cluster 323: current treatment use agents receiving investigational days study prior concurrently
Cluster 324: accountability portability hipaa authorization health informed consent act release personal
Cluster 325: min equation ml modification mdrd diet creatinine renal kidney chronic
Cluster 326: cirrhosis clinically hepatitis liver significant abuse alcohol viral current fatty
Cluster 327: investigational currently receiving agent agents received weeks study participated participating
Cluster 328: mutation egfr activating mutations alk testing nsclc approved patients tumor
Cluster 329: obtained mm registration platelets ml days mcl cells prior si
Cluster 330: situations social compliance illness psychiatric requirements limit uncontrolled situation pectoris
Cluster 331: biopsy prostate histologically cancer pathologically proven adenocarcinoma diagnosis gleason higher
Cluster 332: dehydrogenase deficiency capecitabine fluorouracil fluoropyrimidine phosphate glucose known hereditary irinotecan
Cluster 333: requires transplant organ use history medications transplants fallopian prohibited treatment
Cluster 334: pain rating scale related score cancer does hypercalcemia cognitive memorial
Cluster 335: psoriasis autoimmune vitiligo requiring diabetes manifestations arthritis atopic dermatitis graves
Cluster 336: ptt partial thromboplastin upper normal uln time aptt pt institutional
Cluster 337: fda food studies met institute national nci administration human institutional
Cluster 338: recurrent breast diagnosed cancer prior inoperable history exceptions therapy borderline
Cluster 339: taking currently medication treatments metformin treatment prohibited diabetic reason immunosuppressive
Cluster 340: glioma optic nf tumor location elective pathway anticonvulsants radiographic directed
Cluster 341: mek mitogen braf activated kinase inhibitor raf therapy treatment prior
Cluster 342: provided red evaluable hematologic transfusions toxicity enrolled counts receive platelet
Cluster 343: pet mri fdg contrast ct undergo imaging patients scans scanning
Cluster 344: eligibility pre criteria registration change initiated induction step final met
Cluster 345: unwilling nursing men childbearing employ contraception pregnant potential women reproductive
Cluster 346: testosterone nmol ng levels level dl serum resistant castration androgen
Cluster 347: curative amenable standard available therapy options disease potentially intent locally
Cluster 348: virus hiv hepatitis human immunodeficiency infection active known history positive
Cluster 349: ligation tubal oophorectomy hysterectomy bilateral sterilization menses menopausal surgical reproductive
Cluster 350: agree barrier dose contraception drug study method use sperm donate
Cluster 351: biopsy biopsies undergo tumor core willingness percutaneous diagnosis needle amenable
Cluster 352: consecutive undergone celibate remaining meets orientation regardless sexual potential months
Cluster 353: electrocardiogram msec qtc qt ecg interval corrected ekg clinically screening
Cluster 354: primary site measurable radiation metastatic prior patients disease unknown kind
Cluster 355: bleeding predisposition willebrands von disorders known state inherited diathesis jeopardize
Cluster 356: mouse murine proteins hypersensitivity excipient recombinant formulation known ctla chimeric
Cluster 357: ascites pericardial pleural ray effusion fluid chest significant malignant symptomatic
Cluster 358: urothelial bladder transitional carcinoma histologically cell tract pelvis muscle histologic
Cluster 359: previously bevacizumab therapy prior treated treatment received weeks patients ixazomib
Cluster 360: absorption swallowing difficulty gi oral interfere gastrointestinal hamper tolerance bleeding
Cluster 361: ethnic races groups men trial eligible women restrictions included expiratory
Cluster 362: hcg gonadotropin chorionic beta test pregnancy human pregnant potential sterilization
Cluster 363: lymph nodes axis short node diameter internal axillary lymphadenopathy longest
Cluster 364: alt ast metastases liver uln bilirubin serum times total transaminases
Cluster 365: fvc predicted corrected pulmonary vital fev saturation dlco forced oxygen
Cluster 366: mi myocardial infarction months cva history past accident acute cerebrovascular
Cluster 367: contact interruptions successful true vasectomy sexual condom abstinence agree commit
Cluster 368: progression clinical evidence metastatic documentation radiographic disease receipt documented measurable
Cluster 369: hashimoto inflammatory following syndrome celiac graves consultation diet hypothyroidism disease
Cluster 370: institution normal limit upper bilirubin institutional equal direct uln serum
Cluster 371: adjuvant chemotherapy received cancer therapy prior endocrine treatment metastatic castration
Cluster 372: adequately basal cell skin squamous cancer treated years malignancy carcinoma
Cluster 373: curatively cancer situ treated cervical skin evidence years adequately melanoma
Cluster 374: transplant autologous stem allogeneic cell previous prior rescue patients eligible
Cluster 375: access venous suitable apheresis leukapheresis required line marrow blood peripheral
Cluster 376: attenuated live vaccines vaccination weeks vaccine days prior tremelimumab receipt
Cluster 377: deemed appropriate resection surgical surgery surgeon candidate considered curative chemotherapy
Cluster 378: measurable cm ct lesion tomography dimension longest scan disease dimensional
Cluster 379: care standard supportive therapy clinic accepted ancillary reasons needed progressive
Cluster 380: zone marginal follicular lymphoma extranodal splenic nodal sll mantle lymphocytic
Cluster 381: methods contraception oophorectomy intrauterine contraceptive bearing child effective highly women
Cluster 382: qualify recovered note targeted molecule administered radiation imatinib grade weeks
Cluster 383: biologic cytotoxic chemotherapy immunotherapy weeks weekly nitrosoureas delayed mitomycin extensive
Cluster 384: white wbc blood counts cell cells mm count bil platelet
Cluster 385: nab paclitaxel hypersensitivity weekly cisplatin arm prior chemotherapy received known
Cluster 386: bleeding hemorrhage gastrointestinal clinically significant grade unexplained history entering gi
Cluster 387: plasma leukemia diagnosis cell differential circulating amyloidosis fanconi family fap
Cluster 388: invasion refractory primary disease myelofibrosis cancer mr egfr hours presence
Cluster 389: histologic malignancy diagnosis tumor neuroblastoma nf relapse cytologic pathologically tumors
Cluster 390: cardiac arrhythmias symptomatic uncontrolled ventricular significant disease premature contractions congestive
Cluster 391: informed consent sign written document able willing patient understand provide
Cluster 392: anc neutrophil absolute count platelet greater equal platelets mcl marrow
Cluster 393: vigorous intensity minutes week moderate exercise engage program questionnaire activity
Cluster 394: signing form age time subject years informed consent icf signed
Cluster 395: amplification tumor mutation selective modified receipt act improvement clia treatment
Cluster 396: place crcl gfr filtration glomerular calculated clearance creatinine institutional uln
Cluster 397: investigator protocol requirements comply opinion unable study patient unwilling follow
Cluster 398: excessive alcoholic alcohol supplemental result obstructive day conditions use syndrome
Cluster 399: confound results situation abnormality duration significantly participate risk laboratory trial
Cluster 400: long family syndrome qt personal history prolongation qtc interval risk
Cluster 401: final administration period starting screening drug study heterosexually donate barrier
Cluster 402: ul obtained platelets days registration prior cells enrollment cutaneous weeks
Cluster 403: examination physical digital findings pathologic exam history cytologic radiologic assessed
Cluster 404: absorption gastrointestinal orally administered short cognitively severely impaired egfr likely
Cluster 405: interested trying smoking date current willing zydelig expiratory extensive expression
Cluster 406: hpv polymerase vaccination pcr human status positive tumor exists existing
Cluster 407: il interferon interleukin alpha immunostimulatory limited regimens therapies cycle concomitant
Cluster 408: follicle fsh postmenopausal hormone bilateral amenorrhea stimulating menopausal oophorectomy post
Cluster 409: nonsteroidal asa nsaids inflammatory drugs hypersensitivity days expansion expectancy expected
Cluster 410: interfere opinion investigator pose condition safety disorder risk patient affecting
Cluster 411: oxygen supplemental continuous requiring saturation supplementary air higher requirement room
Cluster 412: gm hemoglobin dl transfusion level achieve reached anemia equal hb
Cluster 413: cerebellar dementia cns injuries epilepsy psychosis ischemia hemorrhage cerebrovascular involvement
Cluster 414: corticosteroids daily prednisone systemic immunosuppressive medications equivalents mg inhaled condition
Cluster 415: concluded rectal exclude standard radiotherapy marrow bone protocol subject experienced
Cluster 416: sterile surgically childbearing potential bilateral hysterectomy postmenopausal suppression amenorrhea sterilized
Cluster 417: breastfeeding pregnant female subjects lactating subject patient intends ineligible patients
Cluster 418: degrees celsius unexplained infection febrile active scheduled hours illness day
Cluster 419: plasma equal dl umol creatinine mg level renal greater serum
Cluster 420: including intercurrent infection limited concurrent illness uncontrolled hospitalization pneumonia complications
Cluster 421: step registration dl randomization days hemoglobin enrollment criteria prior optional
Cluster 422: agreement partners childbearing potential use continue forms highly rate men
Cluster 423: infants nursing females pregnant potential female unknown capable mother breastfeed
Cluster 424: performed initiation uln serum total bilirubin days labs demonstrate lab
Cluster 425: angioplasty syndromes stenting coronary bypass artery controlled including angina cardiac
Cluster 426: radiotherapy palliation field effects weeks better ixazomib limited irradiated involved
Cluster 427: vegf bevacizumab anti sunitinib sorafenib vascular factor pathway receptor growth
Cluster 428: complete questionnaire english ability assistance questionnaires suicidal able ideation index
Cluster 429: medi eligibility ii cohort phase cancer colorectal ovarian small lung
Cluster 430: unstable angina infarction myocardial months heart cardiac congestive failure entry
Cluster 431: vitamin antagonist antagonists warfarin iu supplementation require equivalent anticoagulation requires
Cluster 432: seizure predispose consciousness history condition brain activity loss trauma attack
Cluster 433: hiv immunodeficiency virus human testing known positive infection history patients
Cluster 434: agreed reproductive contraceptive method effective potential participate pregnancy use heterosexually
Cluster 435: absorption gastrointestinal malabsorption stomach affect alter abnormalities resection relevant manifestations
Cluster 436: retain orally oral medications able patient tube feeding swallow medication
Cluster 437: increase associated risk participation investigator illness opinion condition medical meq
Cluster 438: lactating agree feed pregnant feeding females breast stop intend lenalidomide
Cluster 439: hgb hemoglobin dl transfusion blood days allowed permitted criteria prior
Cluster 440: classical hodgkin lymphoma lymphocyte nhl relapsed diagnosis refractory histologically confirmed
Cluster 441: obstructive respiratory coagulation precluding hospitalization restrictive stress illnesses pulmonary requiring
Cluster 442: al amyloidosis primary systemic known light myeloma chain involvement non
Cluster 443: involvement nervous cns lumbar central lymphoma osteoporosis patients known active
Cluster 444: glaucoma macular degeneration decreased heart causes patients known disease history
Cluster 445: rcc clear component histologically confirmed metastatic cell histology histological advanced
Cluster 446: inhibitor kinase treatment received hdac cdk prior therapy inhibitors previous
Cluster 447: splenectomy immunocompromised having undergone prior splenic report irradiation household radical
Cluster 448: independent transfusion platelets ul support mm platelet mcl growth days
Cluster 449: severe uncompensated diatheses respiratory diseases uncontrolled network evidence systemic active
Cluster 450: date randomization radiotherapy surgery days elapsed participant prior major radiation
Cluster 451: threatening life active infection uncontrolled antimicrobial severe visceral disease untreated
Cluster 452: transplantation allograft organ marrow transplant solid allogeneic history bone prior
Cluster 453: entering radiotherapy chemotherapy weeks large nitrosoureas mitomycin therapy study prior
Cluster 454: healed surgery planned incision wound invasive oral fully procedures surgical
Cluster 455: mannitol magnesium excipients experienced external extensive expression exposure expiratory experimental
Cluster 456: chinese hamster ovary hypersensitivity atezolizumab recombinant formulation component antibodies products
Cluster 457: nutrition hydration tube obstruction parenteral dependency routine require requirement signs
Cluster 458: relapse transplant malignancy secondary requires malignancies hematologic acceptable patients treated
Cluster 459: prolymphocytic cr lymphoma undifferentiated biphenotypic initial leukemias nd mantle nhl
Cluster 460: radiation surgery undergoing chemotherapy currently therapy cancer patients neoplastic treatment
Cluster 461: localized antineoplastic expected require form protocol systemic patient therapy study
Cluster 462: event immune adverse related grade unresolved immunotherapy events recovered receiving
Cluster 463: analogs drugs hypersensitivity known components thalidomide anaphylactic study allergy patients
Cluster 464: bmi overweight mass index body weight greater scanner kg equal
Cluster 465: attack transient ischemic cerebrovascular artery accident stent outpatient revascularization bypass
Cluster 466: teaspoon hemoptysis red blood dose episode excess signs hemorrhage month
Cluster 467: options fanca available therapeutic nervous central radiotherapy including metastatic disease
Cluster 468: advanced systemic received metastatic chemotherapy prior disease therapy rcc lines
Cluster 469: count ul mm absolute lymphocyte obtained days registration cells blood
Cluster 470: hrs proteinuria persistent grade hematuria random sample urinalysis gm measured
Cluster 471: approximately remain minutes pet duration hour procedure imaging able patient
Cluster 472: invading esophagus endobronchial rectum cabozantinib tract tumor evidence familial exertion
Cluster 473: monoxide carbon dlco capacity diffusing predicted corrected lung pulmonary hemoglobin
Cluster 474: substance psychological evaluation abuse social results conditions interfere participation study
Cluster 475: illicit alcohol abuse drugs drug regular known active addiction suspected
Cluster 476: contraindications leukapheresis undergo agents donor weeks prior fancc fanca fanconi
Cluster 477: bisphosphonates denosumab atezolizumab ligand initiated continue bisphosphonate treatment allowed patients
Cluster 478: stable decreasing corticosteroids enrollment dose prior patients corticosteroid deficits days
Cluster 479: switched different pointes qt torsades discontinued interval medications medication torsade
Cluster 480: cholangiocarcinoma fibrolamellar hcc mixed diagnosis advanced histologically confirmed carcinoma liver
Cluster 481: histological metastatic diagnosis confirmation cancer breast carcinoma inflammatory adenocarcinoma patients
Cluster 482: childbearing pregnant potential plan breastfeeding excluded currently women intending intend
Cluster 483: access computer internet address regular tablet engage working reached valid
Cluster 484: iiib nsclc iv squamous stage diagnosis cytologically advanced histologically confirmed
Cluster 485: immunotherapy chemotherapy hormonal therapy treatment radiation weeks cancer prior including
Cluster 486: antiarrhythmic class ia iii tachycardia pacemaker block receiving unstable qt
Cluster 487: detained compulsorily prisoners infectious physical illness psychiatric subjects involuntarily incarcerated
Cluster 488: pancreatitis acute chronic history recent entry year symptomatic renal past
Cluster 489: kidney hemodialysis end dialysis involving place undue disease dysfunction stage
Cluster 490: practice signing effective agree time contraception mandated designated principal icf
Cluster 491: pet fit scanner lie flat weighing lbs scanning minutes weight
Cluster 492: distant regional evidence clinical patients induction nodal lymph disease metastasis
Cluster 493: histologically confirmed gliosarcoma glioma glioblastoma recurrent iv diagnosis grade gbm
Cluster 494: japan routine cervical females male age breast years cancer expected
Cluster 495: cerebral meningeal pml progressive underlying hemorrhage participants confirmed related malignancy
Cluster 496: chair slides discussed tissue available compromise enrollment organ ability major
Cluster 497: androgen orchiectomy therapy generation ar agonist releasing antagonist receptor prostate
Cluster 498: antibiotic intravenous requiring systemic infection therapy iv active admission antiviral
Cluster 499: thyroid hormone anaplastic hypothyroidism wnl thyroxine replacement stimulating free limits
Cluster 500: ambulatory walk self purpose devices lansky score ecog age non
Cluster 501: fluency english patient proficient language data lack collection caregiver completion
Cluster 502: tb tuberculosis latent bacillus active ta infection known history patients
Cluster 503: epileptic inducing enzyme antiepileptic phenobarbital carbamazepine phenytoin completion stable involvement
Cluster 504: hypomethylating myelodysplastic mds agent aml syndrome azacitidine cycles response therapy
Cluster 505: investigators makes opinion jeopardize investigator condition unsuitable integrity data make
Cluster 506: cml phase accelerated myelogenous crisis leukemia blast chronic myeloid ph
Cluster 507: smoke tobacco past use smoked cigarettes herbal products receiving day
Cluster 508: sepsis hemodynamic persisting progressing signs symptoms infections infection expected experienced
Cluster 509: anti received monoclonal cd antibody alemtuzumab prior infusion directed cluster
Cluster 510: pregnancy test negative childbearing potential women serum urine hours prior
Cluster 511: leptomeningeal brain presence known history active metastases disease patients metastasis
Cluster 512: bisphosphonate hypercalcemia symptomatic denosumab osteoporosis reasons calcium lack therapy stable
Cluster 513: survival months anticipated estimated month year failure organ illness major
Cluster 514: ketoconazole inhibitor enzalutamide acetate abiraterone ar received therapy treatment prior
Cluster 515: adrenal pituitary insufficiency replacement liver maintenance history thyroxine dysfunction modifying
Cluster 516: comply informed consent ability requirements procedures willingness follow protocol study
Cluster 517: immunosuppressant tacrolimus cyclosporine prednisone concurrent chronic drug systemic dose days
Cluster 518: precautions agree pregnancy counseled fathering avoid exposure contact risks children
Cluster 519: allele hla positive expression cross match cytotoxic central subject donor
Cluster 520: required procedures participate follow willing study purpose circumstances indicating permit
Cluster 521: ipsilateral synchronous breast dcis cancer previous history orchiectomy mastectomy cancers
Cluster 522: aids acquired hiv immunodeficiency syndrome deficiency known related illness human
Cluster 523: locally advanced unresectable metastatic histologically proven confirmed adenocarcinoma resectable patients
Cluster 524: parts studied thrombotic hypersensitivity treatment prior expectancy expiratory experimental experienced
Cluster 525: oxidase inhibitors alpha contraindication allergy use known therapy treatment prior
Cluster 526: common terminology adverse ctcae version events grade alopecia criteria toxicities
Cluster 527: impairment existing renal moderate cardiovascular pre hepatic disease severe ild
Cluster 528: arm exclusion pik randomized nivolumab zydelig exposure treatment prior registration
Cluster 529: polymerase chain pcr reaction hepatitis positive surface antigen antibody antiviral
Cluster 530: unable unwilling written subjects informed consent patients cognitively adults prohibited
Cluster 531: inappropriate make judgment interpretation investigator condition study patient morbidity enzymes
Cluster 532: serology hepatitis cirrhosis positive chronic liver test active alcoholic persistent
Cluster 533: colon diagnosis adenocarcinoma prostate rectum cytologically histologically confirmed breast cancer
Cluster 534: herbal medications prescribed counseled supplements psa products new use patient
Cluster 535: carry activities walk light activity able zydelig extensive expression exposure
Cluster 536: transfusions blood willing donate leukapheresis biopsies products receive product transfusion
Cluster 537: histologically confirmed breast metastatic cytologically invasive primary cancer tnbc cohort
Cluster 538: pelvic previous radiation prior received rt history considered vaginal brachytherapy
Cluster 539: progressive recurrent persistent disease metastatic received patients number progressed regimens
Cluster 540: tests visits scheduled comply laboratory procedures plans willingness willing ability
Cluster 541: hydration supportive preexisting treatments contraindication intolerance impairment concomitant required drugs
Cluster 542: alter absorption vomiting nausea ulcerative diarrhea impairment gi significantly malabsorption
Cluster 543: mgmt methylation gbm testing cohort status tumor expansion exists expectancy
Cluster 544: thrombocytopenia anemia lymphadenopathy doubling dependent pacemaker progressive oxygen transfusion presence
Cluster 545: epidermal factor receptor egfr growth anaplastic alk mutations kinase human
Cluster 546: flow tc stop exist existing exists expansion expectancy expected extranodal
Cluster 547: evaluable radiologically imaging presence phase measurable disease patients parts response
Cluster 548: pancreatic radiation chemotherapy cancer therapy radiotherapy abdominal adenocarcinoma resection surgical
Cluster 549: contraindication mri prophylaxis defibrillator aneurysm concomitant pacemaker hypersensitivity presence medical
Cluster 550: necessary stress physiologic endocrine doses receive steroids allowed patients exists
Cluster 551: allergy iodine intravenous contrast diet sodium gadolinium contraindication reaction ct
Cluster 552: specimens samples tissue tumor offered specimen needle paraffin slides review
Cluster 553: observational intention trials acceptable imaging agents investigational disease therapy exists
Cluster 554: csf colony erythropoietin granulocyte stimulating gm factor filgrastim lumbar cytology
Cluster 555: hbsag antigen hcv antibody test hepatitis positive surface negative virus
Cluster 556: treated brain asymptomatic metastasis stable steroids parenchymal patients active definitive
Cluster 557: encephalitis keratitis intermittent complications lesions skin infection active expiratory extensive
Cluster 558: benefit intolerant therapies available refractory provide clinical known treatment experimental
Cluster 559: tnf azathioprine medications anti systemic immunosuppressant cyclophosphamide thalidomide immunosuppressive dose
Cluster 560: trials clinical trial participation therapeutic concurrent enrollment investigational interventional observational
Cluster 561: father children visit duration breastfeeding trial screening experienced expansion experimental
Cluster 562: partner male vasectomized sterilization end sexual wocbp screening female confirmed
Cluster 563: autoimmune childhood atopy excluded subjects exclusionary suspected injections intermittent disease
Cluster 564: completed second considered melanoma currently skin malignancy active cancers relapse
Cluster 565: nsaid nsaids aspirin inflammatory drugs agents anti use nonsteroidal day
Cluster 566: location lymphodepletion fixed cause procurement obstruction exclusion tumor false falls
Cluster 567: discussed consultation profile benefit determined require eligibility hepatitis patient expansion
Cluster 568: psychiatric alcoholism substance abuse mental disorders disorder addiction bipolar psychosis
Cluster 569: malabsorption absorption interfere syndrome condition precludes intestinal syndromes history administration
Cluster 570: immediate used reaction severe history hypersensitivity cyclophosphamide bendamustine carfilzomib phosphate
Cluster 571: management interstitial suspected toxicity lung interfere pulmonary related symptomatic existing
Cluster 572: evidence progression recurrence disease local intent therapy cancer treatment documented
Cluster 573: circumstances recurrence different individuals following eligible malignancy years cell history
Cluster 574: approval regulatory myelosuppressive indication network process entered open date board
Cluster 575: bearing child breastfeeding pregnant women nursing means pdr using excluded
Cluster 576: staff site applies planning prospective directly present sponsor member involved
Cluster 577: derivative coumadin anticoagulants warfarin therapeutic coumarin anticoagulant sodium anticoagulation taking
Cluster 578: malignancy cervix skin situ free carcinoma non melanoma years cancer
Cluster 579: anesthesia general monitored scanning percutaneous incision require tube placement access
Cluster 580: sub cohorts healthy outpatient aim adult contrast prisoners evaluation type
Cluster 581: eastern oncology cooperative group ecog performance status karnofsky score ps
Cluster 582: dipstick collection urinalysis hour hours protein urine proteinuria demonstrate quantitative
Cluster 583: function values acceptable defined adequate status parameters profile biological outside
Cluster 584: food ancillary investigation fda indication research immunotherapy approved expected exposure
Cluster 585: diaphragm spermicide condom uterine plus hormonal intrauterine barrier abstinence device
Cluster 586: esophageal varices gastric portal biliary encephalopathy bleeding hypertension hepatic months
Cluster 587: sarcoma tissue tumor diagnosis zydelig experienced extensive expression exposure expiratory
Cluster 588: disorders documented autoimmune immunosuppressive history encephalitis epileptic seizures requires inflammatory
Cluster 589: society american cap asa er guidelines receptor physical class iv
Cluster 590: platelets cells granulocytes anc cohort mcl liter discretion plts transfusions
Cluster 591: prolong quality known state survival taking proven concomitant qtc curative
Cluster 592: graft entry hematopoietic stem agents participation cell received patient study
Cluster 593: unsuitable candidate investigators participant receive opinion condition drug study zydelig
Cluster 594: durvalumab tremelimumab reproductive birth effective female employ excipient medi feeding
Cluster 595: craniospinal irradiation xrt weeks tbi cranial palliative pelvis body pelvic
Cluster 596: diarrhea chronic bowel inflammatory gastrointestinal colitis disease symptom history fibrosis
Cluster 597: protein urine mg monoclonal dl serum reactive multiple hr measurable
Cluster 598: hemodynamic exercise failure acute pulmonary uncontrolled family expression exertion exist
Cluster 599: recipient haploidentical donor hla identical related nmdp typing match antibodies
